Advaxis Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has formed a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy. The goal of the collaboration, titled MINE (My Immunotherapy Neo-Epitopes), is to use Advaxis’ Lm Technology to develop neo-epitope immunotherapies based on an individual patient’s tumor (ADXS-NEO). MINE will fir...